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Abstract
Background: Several staging systems for patients with hepatocellular carcinoma (HCC) have been
proposed, but studies of their prognostic accuracy have yielded conflicting conclusions. Stratifying
patients with early HCC is of particular interest because these patients may derive the greatest benefit
from intervention, yet no studies have evaluated the comparative performances of staging systems in
patients with early HCC.
Methods: A retrospective cohort study was performed using data on 379 patients who underwent liver
resection or liver transplantation for HCC at six major hepatobiliary centres in the USA and Europe. The
staging systems evaluated were: the Okuda staging system, the International Hepato-Pancreato-Biliary
Association (IHPBA) staging system, the Cancer of the Liver Italian Programme (CLIP) score, the Barce-
lona Clinic Liver Cancer (BCLC) staging system, the Japanese Integrated Staging (JIS) score and the
American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system,
6th edition. A recently proposed early HCC prognostic score was also evaluated. The discriminative
abilities of the staging systems were evaluated using Cox proportional hazards models and the bootstrap-
corrected concordance index (c).
Results: Overall survival of the cohort was 74% at 3 years and 52% at 5 years, with a median survival
of 62 months. Most systems demonstrated poor discriminatory ability (P > 0.05 on Cox proportional
hazards analysis, c ª 0.5). However, the AJCC/UICC system clearly stratified patients (P < 0.001, c = 0.59),
albeit only into two groups. The early HCC prognostic score also clearly stratified patients (P < 0.001,
c = 0.60) and identified three distinct prognostic groups.
Discussion: The early HCC prognostic score is superior to the AJCC/UICC staging system (6th edition)
for predicting the survival of patients with early HCC after liver resection or liver transplantation. Other
major HCC staging systems perform poorly in patients with early HCC.
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Introduction
Several staging systems have been proposed for patients with
hepatocellular carcinoma (HCC). The Okuda staging system, pro-
posed in 1985, aimed to predict survival in a cohort with relatively
advanced HCC undergoing a variety of surgical and non-surgical
therapies.1 As advances in imaging technology have allowed diag-
nosis of HCC at less advanced stages, several other systems have
been proposed in order to more appropriately stratify patients in
the modern era. Examples of such systems include clinical staging
systems such as the International Hepato-Pancreato-Biliary Asso-
ciation (IHPBA) staging system,2 the Cancer of the Liver Italian
Programme (CLIP) score,3 and the Barcelona Clinic Liver Cancer
(BCLC) staging system.4,5 Two major pathological staging systems
have also been proposed: the Japanese Integrated Staging (JIS)
score (which incorporates the Liver Cancer Study Group of Japan
[LCSGJ] staging system)2,6 and the American Joint Committee on
Cancer (AJCC)/International Union Against Cancer (UICC)
staging system, 6th edition.7,8 The patient cohorts from which
these staging systems were derived varied widely with respect to
tumour burden, underlying liver disease and therapeutic strategy.
Subsequent studies of their prognostic accuracy have yielded
conflicting conclusions depending on the characteristics of the
patient cohorts in which they were evaluated.9–21
Surgical therapy – either liver resection or liver transplantation
– provides the best chance of longterm survival in patients with
HCC. Patients whose disease is too advanced to allow one of
these treatment modalities may undergo other locoregional or
systemic therapies, but generally with inferior results. Addition-
ally, as the incidence of HCC increases in the West and aggressive
screening strategies are put into place for at-risk patients, HCC is
likely to be diagnosed at earlier stages in more patients. As such,
stratifying patients with early HCC is of particular interest, espe-
cially to surgeons, because patients with early HCC have the
potential to derive the greatest benefit from surgical intervention,
follow-up and repeat intervention when indicated. The contro-
versy regarding the appropriate management of patients with
early HCC22–24 makes accurate prognostic stratification of these
patients imperative. Yet, no studies have compared HCC staging
systems using a cohort composed exclusively of patients with
early HCC. Staging system evaluations that include patients with
a wide spectrum of HCC disease do not indicate which staging
system is most appropriate for use in patients with, specifically,
early HCC.
Recently, our group proposed an early HCC prognostic score as
a simple and accurate method to predict survival of patients with
early HCC.25 The early HCC prognostic score was derived using
population-based data on early HCC patients who underwent
liver resection in the USA. However, it has not been externally
validated. To this end, we assessed the discriminative accuracy of
the early HCC prognostic score in an international cohort of
patients who underwent liver resection or liver transplantation.
We also evaluated the comparative performances of the major
established HCC staging systems as applied to patients with, spe-
cifically, early HCC.
Materials and methods
A retrospective cohort study was performed using data on patients
who underwent liver resection or liver transplantation for HCC at
six major hepatobiliary centres in the USA and Europe between
January 1985 and January 2008. This cohort and the data collection
process have been described in detail previously.26 Briefly, data were
collected from participating institutions using standardized data
entry forms and were subsequently synthesized and analysed at the
co-ordinating centre (Johns Hopkins University School of Medi-
cine). All-cause mortality was the endpoint of interest. The 379
patients in the cohort all had early HCC, defined as a solitary
tumour nodule5 cm in size or two to three tumour nodules all
3 cm in size and no radiological or pathological evidence of
major vascular invasion (i.e. macroscopic invasion of the major
branches of the portal vein or hepatic veins) or metastatic disease.
Kaplan–Meier estimates of survival27 and Cox proportional
hazards models28 were used to explore differences in survival
among the strata established by six major staging systems: the
Okuda staging system;1 the IHPBA staging system;2 the CLIP
score;3 the BCLC staging system;4, 5 the JIS score,6 and the AJCC/
UICC staging system (6th edition).8 In order not to bias the analy-
ses against the clinical staging systems as a result of errors in
preoperative assessment, all staging was performed using postop-
erative data based on pathological review. A previously described
early HCC prognostic score25 was also evaluated. This scoring
system allots 1 point each for tumour size > 2 cm, tumour multi-
focality and the presence of microscopic vascular invasion, and
gives a minimum score of 0 and a maximum score of 2 (i.e.,
patients with scores of 2 and 3 are grouped together). Cox pro-
portional hazards models were stratified by type of surgery (liver
resection or liver transplantation). The discriminative abilities of
the staging systems were assessed using the bootstrap-corrected
concordance index (c-statistic), a generalization of the area under
the receiver operating characteristic (ROC) curve that quantifies
the proportion of all patient pairs for whom the predicted and
observed survival outcomes are concordant.29 A c-value of 0.5
indicates no predictive ability compared with chance alone,
whereas a value of 1.0 indicates perfect discrimination. All tests of
statistical significance were two-sided and statistical significance
was established at a = 0.05. Statistical analyses were performed
using stata/MP 10.0 for Windows (StataCorp LP, College
Station, TX, USA). This study was approved by the Johns Hopkins
University School of Medicine Institutional Review Boards.
Results
The cohort used in this analysis consisted of 379 patients, of
whom 245 underwent liver resection and 134 underwent liver
transplantation. The median ages of the resection and transplan-
tation cohorts were 66 years and 55 years, respectively. Overall, 313
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patients were male (83%) and gender distribution was similar in
both groups. Viral hepatitis was present in 262 patients (69%), of
whom 49 had hepatitis B, 194 had hepatitis C, and 19 had both
hepatitis B and C. Alcohol use contributed to liver disease in 140
patients (37%). The median Model for End-stage Liver Disease
(MELD) score was 9 in the liver resection group and 10 in the liver
transplantation group. Overall, 23% of patients had received prior
locoregional therapy (11% of resected patients and 46% of trans-
planted patients).
Patient and tumour characteristics that are relevant to the
staging systems evaluated are described in Table 1. As per the
study inclusion criteria, no patients had massive tumours (>50%
of liver), major vascular invasion or portal vein thrombosis. About
half (49%) the patients who underwent resection and all patients
who underwent transplantation had ascites. Most patients had
well-compensated cirrhosis, as evidenced by their serum albumin
and bilirubin as well as their Child–Pugh classes (81% class A).
Although most tumours were >2 cm in size (n = 289, 76%), a
significant number in both treatment groups (n = 90, 24%) mea-
sured 2 cm. Most patients had solitary tumours (n = 332, 88%)
and few had multifocal tumours (n = 34 with two tumours, n = 13
with three tumours). Consistent with these results, microvascular
invasion was absent in most patients (n = 296, 78%), but present
in a minority (n = 83, 22%).
Overall survival of the cohort was 74% at 3 years and 52% at 5
years, with a median survival of 62 months (Table 2, Fig. 1), con-
sistent with the early stage of all tumours and the surgical therapy
patients received. Briefly, the ability of the staging systems to
stratify patients varied widely. The clinical staging systems
demonstrated poor distinction between prognostic groups. The
Table 1 Patient and tumour characteristics for staging systems
(n = 379)
Variable Resection Transplantation
n % n %
Number of patients 245 134
Ascites
Present 121 49 134 100
Absent 124 51 0 0
Serum albumin
3 g/dl 185 96 90 80
<3 g/dl 8 4 23 20
Serum bilirubin
3 mg/dl 8 4 7 6
<3 mg/dl 214 96 111 94
Serum a-fetoprotein
400 ng/ml 29 13 14 15
<400 ng/ml 195 87 82 85
Child–Pugh class
Class A 233 95 75 56
Class B 12 5 59 44
Tumour size (all 5 cm)
Size in cm, median,
range
3.5 1.0–5.0 2.4 0.5–5.0
Size >2 cm 210 86 79 59
Size 2 cm 35 14 55 41
Multifocality
Yes 15 6 32 24
No 230 94 102 76
Microvascular invasion
Yes 71 29 12 9
No 174 71 122 91
Table 2 Descriptive survival statistics
Stage/score 3-year,
%
5-year,
%
Median,
months
Overall 74 52 62
Okuda staging system
A (n = 73) 75 47 56
B (n = 228) 72 51 63
C (n = 3) 67 67 –
IHPBA staging system
T1 (n = 69) 80 59 82
T2 (n = 284) 72 51 61
T3 (n = 26) 70 51 62
CLIP score
0 (n = 215) 74 51 61
1 (n = 83) 67 47 56
2 (n = 20) 71 47 46
3 (n = 2) 100 100 92
BCLC staging system
0 (n = 69) 80 59 82
A1–A3 (n = 263) 71 50 60
A4 (n = 47) 77 55 62
JIS score
0 (n = 52) 81 65 97
1 (n = 259) 73 49 57
2 (n = 56) 69 57 76
3 (n = 12) 79 47 46
AJCC/UICC staging system
T1 (n = 256) 80 59 80
T2 (n = 123) 59 38 43
Early HCC prognostic score
0 (n = 59) 87 67 97
1 (n = 225) 78 55 74
2 (n = 95) 56 37 38
IHPBA, International Hepato-Pancreato-Biliary Association; CLIP, Cancer
of the Liver Italian Programme; BCLC, Barcelona Clinic Liver Cancer; JIS,
Japanese Integrated Staging; AJCC/UICC, American Joint Committee
on Cancer/International Union Against Cancer, 6th edition; HCC, hepa-
tocellular carcinoma
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Okuda staging system stratified patients into three groups, but the
survival curves for the stage A and stage B groups were nearly
identical (Fig. 2), and the median survival estimates were also very
close (56 vs. 63 months, respectively; Table 2). There was no sta-
tistically significant difference between these groups (P = 0.62;
Table 3), even after excluding the small (n = 3) Okuda stage C
group (P = 0.36). The IHPBA staging system stratified patients
into three groups with weak distinctions between them (median
survival 82, 61 and 62 months, respectively; Table 2, Fig. 3), and
the difference between the groups was not statistically significant
(P = 0.62; Table 3). The CLIP score yielded four groups with
overlapping survival curves (Fig. 4) and no statistically significant
difference between them (P = 0.48; Table 3). There were only two
patients in the group with a CLIP score of 3, but excluding them
from the analysis did not change this conclusion (P = 0.29). In the
BCLC staging system, stages A1–A3 were not further sub-stratified
because all patients had well-compensated portal hypertension.
For this reason, the BCLC staging system identified three groups
with overlapping survival curves (Fig. 5). Stage A4 demonstrated
better survival than stages A1–A3 (median survival of 62 vs. 60
months; Table 2), and the difference between the groups was not
statistically significant (P = 0.74; Table 3).
The pathological staging systems were similarly analysed. The
JIS score yielded four groups with overlapping survival curves
(Fig. 6) and a non-monotonic progression of median survival
estimates (97, 57, 76 and 46 months, respectively; Table 2). Again,
the difference was not statistically significant (P = 0.35; Table 3).
By contrast, the AJCC/UICC staging system stratified early HCC
patients into two groups with median survival lengths of 80 and
43 months, respectively (Table 2, Fig. 7) and with clear differen-
tiation on Cox proportional hazards analysis (P < 0.001; Table 3).
Finally, the early HCC prognostic score yielded three groups with
clearly differentiated survival curves (Fig. 8). It also demonstrated
the widest range of median survival of any of the evaluated staging
systems (97, 74 and 38 months, respectively; Table 2) and a statis-
tically significant difference (P < 0.001).
In all cases, primary modelling of survival was performed by
representing the various stage groupings with indicator variables.
This approach has the advantage of not assuming a constant
incremental effect of advancing tumour stage, but it has the
potential drawback of reducing statistical power. To evaluate the
possibility that some staging systems failed to demonstrate statis-
tically significant differences between strata as a consequence of
our modelling strategy, all systems were also evaluated using
models that treated stage as a continuous variable. This approach
yielded no changes in any of the conclusions regarding the statis-
tical significance of the differences between strata.
Finally, the discriminatory abilities of the staging systems were
assessed by calculating the bootstrap-corrected c-statistics for
each system. Most systems demonstrated poor discriminatory
ability, with c-statistics close to 0.5 (Table 3). However, two staging
systems – the AJCC/UICC staging system (c = 0.59) and the early
HCC prognostic score (c = 0.60) – demonstrated superior dis-
criminatory ability. As noted above, the chief distinction between
these systems was that the AJCC/UICC system includes two stages
relevant to early HCC, whereas the early HCC prognostic score
includes three such groups. Regression analyses and calculation of
bootstrap-corrected c-statistics were also performed separately for
patients who underwent resection (Table 4) and those who under-
went transplantation (Table 5). In these analyses, the AJCC/UICC
staging system and the early HCC prognostic score also demon-
strated superior discriminatory ability.
Discussion
Several staging systems have been proposed for the prognostic
stratification of patients with HCC, but none have been
derived1–4,6–8 or validated9–21 in a cohort of patients with, specifi-
cally, early HCC. Because patients with early HCC are likely to
benefit most from surgical therapy, prediction of their prognosis is
of special interest and usefulness. In this study, we assessed the
comparative performances of several major staging systems for
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Figure 1 Kaplan–Meier survival estimates, all patients
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Figure 2 Kaplan–Meier survival estimates, by Okuda stage
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HCC, focusing on a large international cohort of patients exclu-
sively with early HCC. We found that the AJCC/UICC staging
system and the early HCC prognostic score both provided good
prognostic discrimination, whereas the other major staging
systems performed quite poorly. Surgeons who treat patients with
early HCC should be aware that these other staging systems – the
Okuda staging system, the IHPBA staging system, the CLIP score,
the BCLC staging system and the JIS score – do not appropriately
stratify patients with respect to prognosis when applied to subjects
with early HCC.
The AJCC/UICC staging system (6th edition) is the most widely
used pathological staging system for HCC and has been recom-
mended as the staging system of choice for patients who undergo
liver resection or liver transplantation.30 Indeed, the AJCC/UICC
staging system performed well in our analysis, but its chief limita-
tion when applied to patients with early HCC is that it allows
identification of only two prognostic strata. By contrast, the early
HCC prognostic score, which was developed in a cohort of patients
with early HCC,25 identifies three distinct prognostic strata. The
early HCC prognostic score also provides slightly superior dis-
criminatory ability compared with the AJCC/UICC system, as
evidenced by the c-statistics (0.60 vs. 0.59, respectively). The
c-statistic for the early HCC prognostic score in the present analysis
was identical to that previously reported for a population-based
cohort of early HCC patients who underwent liver resection in the
USA.25 The present work is significant in that it externally validates
the early HCC prognostic score. It also extends our previous find-
ings by using institutional data (vs. population-based registry
data), by including an international cohort of patients, and by
including both liver resection and liver transplantation patients.
Table 3 Cox proportional hazards analyses, all patients (n = 379)*
Stage/score HR 95% CI P-value c-statistic
Okuda staging system
A (n = 73) Ref. – 0.62 0.50
B (n = 228) 0.85 0.58–1.24
C (n = 3) 1.52 0.20–11.67
IHPBA staging system
T1 (n = 69) Ref. – 0.62 0.52
T2 (n = 284) 1.11 0.72–1.70
T3 (n = 26) 1.42 0.71–2.83
CLIP score
0 (n = 215) Ref. – 0.48 0.51
1 (n = 83) 1.32 0.89–1.94
2 (n = 20) 1.56 0.70–3.46
3 (n = 2) 1.45 0.19–10.9
BCLC staging system
0 (n = 69) Ref. – 0.74 0.51
A1–A3 (n = 263) 1.11 0.72–1.71
A4 (n = 47) 1.26 0.70–2.29
JIS score
0 (n = 52) Ref. – 0.35 0.52
1 (n = 259) 1.23 0.76–2.00
2 (n = 56) 1.53 0.83–2.81
3 (n = 12) 2.32 0.85–6.36
AJCC/UICC staging system
T1 (n = 256) Ref. – <0.001 0.59
T2 (n = 123) 2.17 1.61–2.93
Early HCC prognostic score
0 (n = 59) Ref. – <0.001 0.600
1 (n = 225) 1.18 0.72–1.95
2 (n = 95) 2.46 1.44–4.19
*All models were stratified by type of surgery to account for differential survival between treatment modalities
HR, hazard ratio; CI, confidence interval; Ref., referent; IHPBA, International Hepato-Pancreato-Biliary Association; CLIP, Cancer of the Liver Italian
Programme; BCLC, Barcelona Clinic Liver Cancer; JIS, Japanese Integrated Staging; AJCC/UICC, American Joint Committee on Cancer/International
Union Against Cancer, 6th edition; HCC, hepatocellular carcinoma
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Figure 3 Kaplan–Meier survival estimates, by International Hepato-
Pancreato-Biliary Association (IHPBA) T-classification
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Figure 4 Kaplan–Meier survival estimates, by Cancer of the Liver
Italian Programme (CLIP) score
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Figure 5 Kaplan–Meier survival estimates, by Barcelona Clinic Liver
Cancer (BCLC) stage
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Figure 6 Kaplan–Meier survival estimates, by Japanese Integrated
Staging (JIS) score
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Figure 7 Kaplan–Meier survival estimates, by American Joint Com-
mittee on Cancer/International Union Against Cancer (AJCC/UICC),
6th edition, T-classification
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Figure 8 Kaplan–Meier survival estimates, by early hepatocellular
carcinoma prognostic score
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Both the AJCC/UICC staging system and the early HCC prog-
nostic score were developed based on rigorous analyses of clini-
copathological data from patients with resected HCC.7,25 The
main difference between the approaches taken by these two
systems is that the early HCC prognostic score allows patients
with solitary tumours to be stratified with respect to both tumour
size (>2 cm vs. 2 cm) and the presence of microvascular inva-
sion, whereas the AJCC/UICC system does not consider size to be
a prognostic factor for solitary tumours. A recent analysis evalu-
ated a modified version of the AJCC/UICC staging system (6th
edition) that: (i) further stratifies solitary tumours without
microvascular invasion based on a 2-cm size cut-off, and (ii)
further stratifies multifocal tumours of 5 cm in size (T2) based
on the presence or absence of macroscopic vascular invasion.31
That study found that such modification enhanced the predictive
ability of the standard AJCC/UICC staging system (6th edition).31
Interestingly, the approach taken was similar (although not iden-
tical) to that proposed in the early HCC prognostic score, which
also recognizes the additional prognostic impact of tumour size
>2 cm for both solitary and multifocal tumours and the additional
prognostic impact of microvascular invasion in multifocal
tumours.
Previous studies that have failed to find prognostic value in a
2-cm size cut-off for solitary tumours may have included too few
patients with small tumours.2,7,9 Data on Japanese patients,18
however, demonstrated the prognostic value of a 2-cm cut-off,
perhaps because of the higher proportion of patients diagnosed in
the early stages, and the 2-cm cut-off is an important component
of the LCSGJ staging system2 and, consequently, the JIS score.6 In
the present study, 24% of patients had tumours2 cm in size and
Table 4 Cox proportional hazards analyses, liver resection (n = 245)
Stage/score HR 95% CI P-value c-statistic
Okuda staging system
A (n = 73) Ref. – 0.02 0.49
B (n = 116) 0.84 0.57–1.22
C (n = 2) 119 7.09–1993
IHPBA staging system
T1 (n = 30) Ref. – 0.92 0.48
T2 (n = 205) 0.96 0.58–1.60
T3 (n = 10) 0.82 0.30–2.22
CLIP score
0 (n = 180) Ref. – 0.45 0.51
1 (n = 41) 1.20 0.76–1.88
2 (n = 3) 2.34 0.57–9.57
3 (n = 0) – –
BCLC staging system
0 (n = 30) Ref. – 0.87 0.49
A1–A3 (n = 200) 0.97 0.58–1.61
A4 (n = 15) 0.80 0.33–1.94
JIS score
0 (n = 29) Ref. – 0.65 0.51
1 (n = 197) 0.93 0.56–1.54
2 (n = 17) 1.30 0.61–2.79
3 (n = 2) 2.23 0.29–16.9
AJCC/UICC staging system
T1 (n = 164) Ref. – <0.001 0.59
T2 (n = 81) 2.14 1.53–3.00
Early HCC prognostic score
0 (n = 25) Ref. – 0.001 0.58
1 (n = 146) 1.04 0.56–1.90
2 (n = 74) 2.01 1.07–3.79
HR, hazard ratio; CI, confidence interval; Ref., referent; IHPBA, International Hepato-Pancreato-Biliary Association; CLIP, Cancer of the Liver Italian
Programme; BCLC, Barcelona Clinic Liver Cancer; JIS, Japanese Integrated Staging; AJCC/UICC, American Joint Committee on Cancer/International
Union Against Cancer, 6th edition; HCC, hepatocellular carcinoma
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this factor probably explains part of the advantage of the early
HCC prognostic score over the AJCC/UICC staging system in this
cohort with early HCC.
Strengths of the present analysis include the fact that its data
were gathered from a large, international cohort. The cohort
included both liver resection and liver transplantation patients,
which allows the results to be generalized to both groups. The
accuracy of clinical staging systems may be limited both by the
staging systems themselves and by inaccuracies in the data used to
stage patients. For example, the imaging modality used or the
progression of the tumour during the interval between imaging
and surgery may decrease the apparent accuracy of a clinical
staging system. Because we based all staging on pathological data,
our analysis assumed the best possible performance of the clinical
staging systems under circumstances of completely accurate data
on tumour number and size. Several limitations should also be
considered. The absence of certain data precluded some patients
from being assigned a CLIP score or Okuda stage, which may
have affected the assessment of these systems’ predictive abilities.
Additionally, data limitations prevented the sub-stratification of
BCLC stages A1–A3. However, because stage A4 demonstrated
better survival than stages A1–A3, further sub-stratification
would still have resulted in at least one of the stages A1, A2 or A3
indicating worse survival than stage A4. As such, the BCLC
staging system would still have demonstrated considerable draw-
backs in this cohort. Finally, because data were retrospectively
acquired from several institutions, pathological review was not
standardized.
In summary, both the AJCC/UICC staging system (6th edition)
and the early HCC prognostic score allow stratification of patients
with early HCC undergoing liver resection or liver transplanta-
tion. Other major staging systems perform inadequately in this
group of patients. We recommend the early HCC prognostic score
for use in studies that focus on patients with early HCC undergo-
ing liver resection or liver transplantation.
Conflicts of interest
None declared.
Table 5 Cox proportional hazards analyses, liver transplantation (n = 134)*
Stage/score HR 95% CI P-value c-statistic
IHPBA staging system
T1 (n = 39) Ref. – 0.15 0.56
T2 (n = 79) 1.36 0.63–2.96
T3 (n = 16) 2.82 1.04–7.67
CLIP score
0 (n = 35) Ref. – 0.60 0.54
1 (n = 42) 1.77 0.75–4.18
2 (n = 17) 1.63 0.56–4.69
3 (n = 2) 1.69 0.21–13.6
BCLC staging system
0 (n = 39) Ref. – 0.28 0.54
A1–A3 (n = 63) 1.34 0.60–3.00
A4 (n = 32) 2.02 0.84–4.84
JIS score
0 (n = 23) Ref. – 0.07 0.52
1 (n = 62) 3.78 1.11–12.9
2 (n = 39) 3.22 0.91–11.4
3 (n = 10) 5.11 1.13–23.1
AJCC/UICC staging system
T1 (n = 92) Ref. – 0.02 0.58
T2 (n = 42) 2.29 1.19–4.42
Early HCC prognostic score
0 (n = 34) Ref. – 0.01 0.60
1 (n = 79) 1.39 0.59–3.28
2 (n = 21) 4.24 1.58–11.3
*The Okuda staging system was omitted because observations in stages A (n = 0) and C (n = 1) were too few
HR, hazard ratio; CI, confidence interval; Ref., referent; IHPBA, International Hepato-Pancreato-Biliary Association; CLIP, Cancer of the Liver Italian
Programme; BCLC, Barcelona Clinic Liver Cancer; JIS, Japanese Integrated Staging; AJCC/UICC, American Joint Committee on Cancer/International
Union Against Cancer, 6th edition; HCC, hepatocellular carcinoma
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